Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04732949 · ClinicalTrials.gov registry record · Phase 3
Study to Assess Efficacy and Safety of Inhaled Interferon-β Therapy for COVID-19
A Phase 3 study, sponsored by Synairgen Research.
- Completed
- Registry status
- Phase 3
- Development phase
- 623
- Enrollment target
NCT04732949: Completed Phase 3 study, sponsored by Synairgen Research.
NCT04732949 is a Phase 3 study that has completed, run by Synairgen Research. The registered enrollment target is 623 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (19% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04732949, a Phase 3 study, has completed, sponsored by Synairgen Research.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 623 participants
- Enrollment target
Study Summary
The purpose of this Phase III study is to confirm that SNG001 can accelerate the recovery of hospitalised patients receiving oxygen with confirmed Severe Acute Respiratory Syndrome coronavirus 2 (SARS-CoV-2). Safety and other efficacy endpoints will also be assessed.
Primary Outcome
The time to hospital discharge in patients with moderate COVID-19 after administration of SNG001 compared to placebo was evaluated.
Interventions
- DRUG Placebo
- DRUG SNG001
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 623 participants |
| Start Date | 2021-01-12 |
| Est. Completion | 2022-02-10 |
| Phase | Phase 3 |
What the finished NCT04732949 record still lists
NCT04732949 is an interventional study that assigns participants to a tested intervention. The registered 623 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (19% lower).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04732949 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04732949 about?
NCT04732949 is a clinical study titled "Study to Assess Efficacy and Safety of Inhaled Interferon-β Therapy for COVID-19". The purpose of this Phase III study is to confirm that SNG001 can accelerate the recovery of hospitalised patients receiving oxygen with confirmed Severe Acute Respiratory Syndrome coronavirus 2 (SARS-CoV-2). Safety and other efficacy endpoints will also be assessed.
What is the current status of trial NCT04732949?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 623 participants. The study started on 2021-01-12. Estimated completion is 2022-02-10.
What interventions are being tested in trial NCT04732949?
The interventions under investigation include: Placebo (DRUG), SNG001 (DRUG).
Who is sponsoring clinical trial NCT04732949?
This trial is sponsored by Synairgen Research, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04732949's enrollment target sits among peer trials
623 588th of 2000 higher than 1,413 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06406049 · 624 participants · NA
Finishing HIV Project
- NCT05349227 · 625 participants · NA
Comprehensive Outcomes for After Cancer Health
- NCT06103864 · 625 participants · Phase 3
A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer
- NCT06230510 · 625 participants · NA
Milk-Tot Study: Impact of Whole Versus Low-fat Milk on Child Health
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI